The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

The US Food and Drug ... approval was based on the open-label BASIS trial in 116 men and boys with either severe hemophilia A or B without factor inhibitors. During the trial's first 6 months ...

A nasal spray version of the annual flu vaccine can now be taken at home, the U.S. Food and Drug Administration (FDA) says. In a statement published Sept. 20, the FDA announced that it had ...

Opens in a new tab or window The FDA approved marstacimab ... It is the first anti-TFPI approved in the U.S. for the treatment of hemophilia A or B. "Today's approval of Hympavzi provides patients ...

Opens in a new tab or window The FDA on Thursday approved xanomeline and trospium ... (P<0.0001 for both): EMERGENT-2: -21.2 vs -11.6, respectively EMERGENT-3: 20.6 vs -12.2 And some key secondary ...

A rush of Instagram-approved products have flooded the NRT market over the last few years. They have a new audience in mind: ...

Eczema, also known as atopic dermatitis, is an inflammatory skin condition that can cause itching, rashes and dry patches. The FDA's approval was ... in Black patients 6:38 PM UTC Oil prices ...

A home version of the nasal flu vaccine FluMist was just approved by the U.S. Food and Drug Administration ... subtypes A and B. Adults 50 and older and children between 6 months and 2 years ...

A new gene therapy approved earlier this year can serve as a sustainable single-dose treatment for people with hemophilia B ... finds 6% of U.S. adults have ADHD amid ongoing drug shortages ...

The drug is now pending a final decision from the European Commission. The EMA granted Hympavzi orphan status for treating hemophilia B in December ... or factor IX over a 6-month observational ...